Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Genmab Stories

2010-09-15 07:01:00

BOTHELL, Wash., Sept. 15 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech companies and placed it on the annual Fierce 15. The list, published annually by FierceBiotech, highlights 15 of the top privately held biotech companies out of hundreds of nominees. The list is based on a variety of factors, such as the strength of a company's technology, partnerships and a competitive market position. A complete list of...

2010-09-14 06:30:00

PHILADELPHIA, Sept. 14 /PRNewswire/ -- TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma (PTCL) were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma. Twenty-one adult patients with relapsed or...

2010-09-07 06:30:00

PHILADELPHIA, Sept. 7 /PRNewswire/ -- TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from...

2010-07-01 11:16:00

LONDON and COPENHAGEN, Denmark, July 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications. Genmab will receive an upfront payment of GBP 90 million (DKK 815...

2010-04-29 13:54:00

PHILADELPHIA, April 29 /PRNewswire/ -- TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute (NCI) to conduct an investigator sponsored Phase II clinical trial. For this study, the NCI's Surgery Branch Chief, Dr. Steven A. Rosenberg, will lead a Phase II clinical trial investigating the combination of TenX Biopharma's zanolimumab, an investigational anti-CD4 therapeutic antibody, with aldesleukin (IL-2) for the treatment of...

2010-02-04 13:16:00

PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN). Under the terms of the agreement, Genmab will receive an up-front license fee of USD 4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX will be responsible for all future costs of developing,...

2010-01-15 10:06:00

SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting. This report, entitled "Thought...

2009-11-06 09:37:00

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus. "Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people...

2009-11-05 11:09:00

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight http://www.reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Competitive-Landscape-and-Pipeline-Insight.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24...

2009-10-26 14:14:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment http://www.reportlinker.com/p0156557/Reportlinker-Adds-Monoclonal-Antibodies-Pipeline-Analysis-and-Competitive-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire In the nearly 35 years since the first process for creating mAbs was introduced, they...